San Francisco, California, May 17, 2017 : Most parts of Africa as well as Central and South Americas are the regions that are presenting the maximum demand in the yellow fever treatment market, according to a report by TMR Research. The report, titled “Yellow Fever Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025,” also detects that efforts from globally recognized health organizations such as the UNICEF and the WHO is consistently increasing, which will further favor the demand in this market during the forecast period.
The report has been prepared to act as a credible business document for audiences such as manufacturers of drugs that treat yellow fever, research institutes that are indulged in developing new vaccination for this mosquito-borne disease, and distributors and traders operating in the pharmaceuticals industry. The report provides an in-depth analysis of all the factors that may influence the demand for yellow fever treatment in the near future, evaluates the opportunities available for the vendors until 2025, and also profiles a number of key players functional in this market in order to represent the competitive landscape.
The TMR report observes that while African region remains the most highly affected region, this disease can be transmitted across other countries via infected travelers, which is why the demand for efficient vaccine is escalating. Mosquitoes that cause yellow fever breed in still water or in an unhealthy environment. Consequently, factors such as unhygienic lifestyle, improve healthcare infrastructure in several emerging economies, and growing awareness among wider population regarding the availability of new treatments are expected to drive the demand in the yellow fever treatment market. On the other hand, yellow fever vaccine are not recommended for children below 9 months of age, cancer patients, pregnant women, and compromised immune system, which is hindering the market from achieving its full potential, unless some more effective vaccinations are formulated.
According to the estimates released by the UNICEF, demand for yellow fever drugs was 44% more than the supply, despite the procurement of every viable vaccine by the healthcare organization. UNICEF currently procured nearly 34 million yellow fever vaccinations but the demand continues to surge. Several new companies with financial might have recently invested for the research and development of yellow fever treatment vaccines, and pipeline drugs such as LCTA-949, DiTu, YF-17D, and Flaviviruses infection vaccine are expected to meet the demand during the forecast period.
Themis Bioscience GmbH, Panacea Biotech Limited, Janssen Pharmaceutcals Inc., and Arbovax Inc. are some of the key companies currently operating in the yellow fever treatment market. Several other companies are expected to join this market and intensify the competitive landscape but there is enough fodder for all the players in this market, which will ensure a consistent growth in the near future.